Skip to main content

Foot Dermatoses

3
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
3
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Galderma
GaldermaTX - Dallas
3 programs
3
Loceryl NLPhase 41 trial
Loceryl NL + Cosmetic varnishPhase 41 trial
Loceryl Nail LacquerPhase 41 trial
Active Trials
NCT02679911Completed20Est. Jun 2016
NCT02321098Completed50Est. Jan 2016
NCT02705664Completed22Est. Sep 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GaldermaLoceryl Nail Lacquer
GaldermaLoceryl NL
GaldermaLoceryl NL + Cosmetic varnish

Clinical Trials (3)

Total enrollment: 92 patients across 3 trials

NCT02705664GaldermaLoceryl Nail Lacquer

Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1%

Start: Jan 2016Est. completion: Sep 201622 patients
Phase 4Completed

Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer

Start: Sep 2015Est. completion: Jun 201620 patients
Phase 4Completed
NCT02321098GaldermaLoceryl NL + Cosmetic varnish

Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish

Start: Feb 2014Est. completion: Jan 201650 patients
Phase 4Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.